News | 03 April 2026
Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
Its a major breakthrough for women’s ovarian cancer care in Europe
Its a major breakthrough for women’s ovarian cancer care in Europe
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
This marks a meaningful step in the company's continued expansion in the region
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The new assay consolidates screening for four major viral threats into a single workflow
Subscribe To Our Newsletter & Stay Updated
